CoChat
Sign Up
Cited by 26

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Erythrocyte fatty acids as potential biomarkers in the diagnosis of advanced lung adenocarcinoma, lung squamous cell carcinoma, and small cell lung cancer.

de Castro, Javier, MD, Rodríguez, Marina C., Martínez-Zorzano, Vicenta S., Sánchez-Rodríguez, Patricia, Sánchez-Yagüe, Jesús·2014·American Journal of Clinical Pathology
DOI 10.1309/ajcp1quqqllt8bli
Open this paper in CoChat — free account

Abstract

Objectives To analyze the fatty acid profiles of erythrocyte total lipids from patients with advanced squamous cell lung carcinoma (SCC), lung adenocarcinoma (ADC), and small cell lung cancer (SCLC) and benign lung diseases (chronic obstructive pulmonary disease [COPD] and asthma) to reveal the fatty acids that could be used as lung cancer biomarkers. Methods Thirty, 20, 15, 17, and 19 patients with SCC, ADC, SCLC, COPD, and asthma, respectively, and 55 healthy participants were enrolled in our study. Fatty acid profiles were investigated using gas chromatography/mass spectrometry followed by receiver operating characteristic (ROC) curve analysis. Sialic acid (SA) and cytokeratins were measured by the thiobarbituric acid and immunoradiometric methods, respectively. Results At least one of the main fatty acids might be used as a biomarker for every type of lung cancer: arachidonic (20:4n6), linoleic (18:2n6), and stearic (18:0) acids for ADC, SCC, and SCLC, respectively. These fatty acids showed diagnostic yields and operating characteristics similar to or higher than the commonly used SA or cytokeratin markers. Conclusions Fatty acids from erythrocyte total lipids might be used as diagnostic biomarkers of lung ADC, SCC, and SCLC. Their use in different aspects of the disease process needs to be explored.

Overview

Integrity signals

Registry

Crossref · 10.1309/ajcp1quqqllt8bli

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Research works printed but not linked: 50

  1. Monge-Corella, 2008, Lung cancer mortality in towns near paper, pulp and board industries in Spain: a point source pollution study, BMC Public Health, 8, 288, 10.1186/1471-2458-8-288 · DOI
  2. Siegel, 2012, Cancer statistics, 2012, CA Cancer J Clin, 62, 10, 10.3322/caac.20138 · DOI · Paper page
  3. Becker, 2012, LC-MS–based metabolomics in the clinical laboratory, J. Chromatogr B, 883
  4. Patterson, 2011, Aberrant lipid metabolism in hepatocellular carcinoma revealed by plasma metabolomics and lipid profiling, Cancer Res, 71, 6590, 10.1158/0008-5472.CAN-11-0885 · DOI
  5. Newcomer, 2001, The association of fatty acids with prostate cancer risk, Prostate, 47, 262, 10.1002/pros.1070 · DOI
  6. Pala, 2001, Erythrocyte membrane fatty acids and subsequent breast cancer: a prospective Italian study, J Natl Cancer Inst, 93, 1088, 10.1093/jnci/93.14.1088 · DOI
  7. Mikirova, 2004, Erythrocyte membrane fatty acid composition in cancer patients, P R Health Sci J, 23, 107
  8. Santos, 1991, Enhancement of platelet reactivity and modulation of eicosanoid production by intact erythrocytes: a new approach to platelet activation and recruitment, J Clin Invest, 87, 571, 10.1172/JCI115032 · DOI
  9. Prisco, 1995, Platelet activation and platelet lipid composition in pulmonary cancer, Prostaglandins Leukot Essent Fatty Acids, 53, 65, 10.1016/0952-3278(95)90085-3 · DOI
  10. Brittain, 2001, Activation of sickle red blood cell adhesion via integrin-associated protein/CD47-induced signal transduction, J Clin Invest, 107, 1555, 10.1172/JCI10817 · DOI
  11. Hernández-Hernández, 2006, Alterations in erythrocyte membrane protein composition in advanced non–small cell lung cancer, Blood Cell Mol Dis, 36, 355, 10.1016/j.bcmd.2006.02.002 · DOI
  12. de Castro, 2006, Comparison of changes in erythrocyte and platelet fatty acid composition and protein oxidation in advanced non–small cell lung cancer, Cancer Invest, 24, 339, 10.1080/07357900600705250 · DOI
  13. de Castro, 2007, Comparison of changes in erythrocyte and platelet phospholipid and fatty acid composition and protein oxidation in chronic obstructive pulmonary disease and asthma, Platelets, 18, 43, 10.1080/09537100600800776 · DOI
  14. Groopman, 1999, Chemotherapy-induced anemia in adults: incidence and treatment, J Natl Cancer Inst, 91, 1616, 10.1093/jnci/91.19.1616 · DOI
  15. Crawford, 2004, The red blood cell and vascular function in health and disease, Antioxid. Redox Signal, 6, 992
  16. Altiay, 2007, High plasma D-dimer level is associated with decreased survival in patients with lung cancer, Clin Oncol, 19, 494, 10.1016/j.clon.2007.04.002 · DOI
  17. de Castro, 2008, Erythrocyte and platelet phospholipid fatty acids as markers of advanced non-small cell lung cancer: comparison with serum levels of sialic acid, TPS and Cyfra 21-1, Cancer Invest, 26, 407, 10.1080/07357900701788114 · DOI
  18. de Castro, 2009, Platelet linoleic acid is a potential biomarker of advanced non-small cell lung cancer, Exp Mol Pathol, 87, 226, 10.1016/j.yexmp.2009.08.002 · DOI
  19. Patel, 1989, Significance of serum sialoglycoproteins in patients with lung cancer, Neoplasma, 36, 53
  20. Stringou, 1992, Serum sialic acid (TSA/LSA) and carcinoembryonic antigen (CEA) levels in cancer patients undergoing radiotherapy, Anticancer Res, 12, 251
  21. Patel, 1995, Comparison between serum levels of carcinoembryonic antigen, sialic acid and phosphohexose isomerase in lung cancer, Neoplasma, 42, 271
  22. Buccheri, 2001, Cytokeratin-derived markers of lung cancer, Expert Rev Mol Diagn, 1, 315, 10.1586/14737159.1.3.315 · DOI
  23. Calikoglu, 2002, The levels of serum vitamin C, malonyldialdehyde and erythrocyte reduced glutathione in chronic obstructive pulmonary disease and in healthy smokers, Clin Chem Lab Med, 40, 1028, 10.1515/CCLM.2002.179 · DOI
  24. Prisco, 1986, Increased thromboxane A2 generation and altered membrane fatty acid composition in platelets from patients with active angina pectoris, Thrombosis Res, 44, 101, 10.1016/0049-3848(86)90185-4 · DOI
  25. Prisco, 1989, Altered membrane fatty acid composition and increased thromboxane A2 generation in platelets from patients with diabetes, Prostaglandins Leukot Essent Fatty Acids, 35, 15, 10.1016/0952-3278(89)90011-2 · DOI
  26. Kaplan, 1981, Plasma levels of beta-thromboglobulin and platelet factor 4 as indices of platelet activation in vivo, Blood, 57, 199, 10.1182/blood.V57.2.199.199 · DOI
  27. Aminoff, 1961, Methods for the quantitative estimation of N-acetylneuraminic acid and their application to hydrolysates of sialomucoids, Biochem J, 81, 384, 10.1042/bj0810384 · DOI
  28. Warren, 1959, The thiobarbituric acid assay of sialic acids, J Biol Chem, 234, 1971, 10.1016/S0021-9258(18)69851-5 · DOI
  29. Gornall, 1949, Determination of serum proteins by means of Biuret reaction, J Biol Chem, 177, 751, 10.1016/S0021-9258(18)57021-6 · DOI
  30. López-Revuelta, 2005, Increase in vulnerability to oxidative damage in cholesterol-modified erythrocytes exposed to t-BuOOH, Biochim Biophys Acta, 1734, 74, 10.1016/j.bbalip.2005.02.004 · DOI
  31. Rothman, 1990, No adjustments are needed for multiple comparisons, Epidemiology, 1, 43, 10.1097/00001648-199001000-00010 · DOI · Paper page
  32. Perneger, 1998, What’s wrong with Bonferroni adjustments, Br Med J, 316, 1236, 10.1136/bmj.316.7139.1236 · DOI · Paper page
  33. Park, 2004, Receiver operating characteristic (ROC) curve: practical review for radiologists, Korean J Radiol, 5, 11, 10.3348/kjr.2004.5.1.11 · DOI
  34. Burgueño, 1995, Las curvas ROC en la evaluación de las pruebas diagnósticas, Med Clin (Barc), 104, 661
  35. DeBerardinis, 2012, Cellular metabolism and disease: what do metabolic outliers teach us?, Cell, 148, 1132, 10.1016/j.cell.2012.02.032 · DOI · Paper page
  36. Xu, 2013, Global and targeted metabolomics of esophageal squamous cell carcinoma discovers potential diagnostic and therapeutic biomarkers, Mol Cell Proteomics, 2, 1306, 10.1074/mcp.M112.022830 · DOI
  37. Wen, 2013, Exploratory investigation of plasma metabolomics in human lung adenocarcinoma, Mol Biosyst, 9, 2370, 10.1039/c3mb70138g · DOI
  38. Straface, 2002, Structural changes of the erythrocyte as a marker of non–insulin-dependent diabetes: protective effects of N-acetylcysteine, Biochem Biophys Res Commun, 290, 1393, 10.1006/bbrc.2002.6340 · DOI
  39. Bordin, 2013, Human red blood cells alterations in primary aldosteronism, J Clin Endocrinol Metab, 98, 2494, 10.1210/jc.2012-3571 · DOI
  40. Váli, 2008, Oxidative stress with altered element content and decreased ATP level of erythrocytes in hepatocellular carcinoma and colorectal liver metastases, Eur J Gastroenterol Hepatol, 20, 393, 10.1097/MEG.0b013e3282f495c7 · DOI
  41. Harris, 2005, Fatty acid composition of red blood cell membranes and risk of squamous cell carcinoma of the skin, Cancer Epidemiol Biomarkers Prev, 14, 906, 10.1158/1055-9965.EPI-04-0670 · DOI
  42. Khyshiktuev, 1994, Fatty acid composition of blood plasma lipids and erythrocytes in lung cancer patients [in Russian], Vopr Med Khim, 40, 48
  43. Minetti, 2008, Radical generation and alterations of erythrocyte integrity as bioindicators of diagnostic or prognostic value in COPD?, Antioxid Redox Signal, 10, 829, 10.1089/ars.2007.1864 · DOI
  44. Pidgeon, 2007, Lipoxigenase metabolism: roles in tumor progression and survival, Cancer Metastasis Rev, 26, 503, 10.1007/s10555-007-9098-3 · DOI
  45. Sakai, 2012, Arachidonic acid and cancer risk: a systematic review of observational studies, BMC Cancer, 12, 606, 10.1186/1471-2407-12-606 · DOI
  46. Pujol, 1996, Cytokeratins as serum markers in lung cancer: a comparison of Cyfra 21-1 and TPS, Am J Respir Crit Care Med, 154, 725, 10.1164/ajrccm.154.3.8810612 · DOI
  47. Okamura, 2013, Diagnostic value of CEA and CYFRA 21-1 tumor markers in primary lung cancer, Lung Cancer, 80, 45, 10.1016/j.lungcan.2013.01.002 · DOI
  48. Alatas, 2001, Diagnostic value of CEA, CA 15-3, CA 19-9, Cygra 21-1, NSE and TSA assay in pleural effusions, Lung Cancer, 31, 9, 10.1016/S0169-5002(00)00153-7 · DOI
  49. Narayanan, 1994, Sialic acid as a tumor marker, Ann Clin Lab Sci, 24, 376
  50. Feijoo-Carnero, 2004, Clinical significance of preoperative serum sialic acid levels in colorectal cancer: utility in the detection of patients at high risk of tumor recurrence, Int J Biol Markers, 19, 38, 10.1177/172460080401900105 · DOI

Cited by

Sorted by citations

See all 26

Metadata

Authors
de Castro, J., MD, Rodríguez, M. C., Martínez-Zorzano, V. S., Sánchez-Rodríguez, P., & Sánchez-Yagüe, J.
Affiliations
  • Radiology Service, Santísima Trinidad Foundation Hospital, Salamanca, Spain
  • Lung Diseases Service, Santísima Trinidad Foundation Hospital, Salamanca, Spain
  • Department of Biochemistry, Genetics and Immunology, University of Vigo, Vigo, Spain
  • Department of Biochemistry and Molecular Biology, University of Salamanca, Salamanca, Spain.
Venue
American Journal of Clinical Pathology
Publisher
Oxford University Press (OUP)
Published
2014-07-01
Volume
142
Issue
1
Pages
111-120
ISSN
  • 1943-7722
  • 0002-9173
DOI
10.1309/ajcp1quqqllt8bli
Cited by
26
References
2
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review